CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EpCAM inhibitors(Epithelial cell adhesion molecule inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

+ [1]

Therapeutic Areas

Other DiseasesNeoplasmsDigestive System Disorders+ [1]

Active Indication

EpCAM positive Solid TumorsMalignant ascitesAdvanced gastric carcinoma+ [2]

Inactive Indication

CarcinomaColonic CancerColorectal Cancer+ [5]

Originator Organization

Neovii Biotech GmbH

Active Organization

Lindis Biotech GmbhLinton Pacific Ag

Guangzhou LintonPharm Co Ltd

+ [1]

Inactive Organization

Neovii Biotech GmbH

Vetter Pharma-Fertigung GmbH & Co. KG

Drug Highest PhaseApproved

First Approval Date

European Union (20 Apr 2009),

Malignant ascites

RegulationOrphan Drug (European Union)

Clinical Trials associated with Catumaxomab

NCT04799847

/ RecruitingPhase 1/2

A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who have Failed or are Intolerant to Bacillus Calmette-Guerin (BCG) Vaccine

Start Date23 Nov 2021

Sponsor / Collaborator

LintonPharm Co.,Ltd.

CTR20210616

/ RecruitingPhase 1/2

一项观察卡妥索单抗对卡介苗治疗失败或不耐受的非肌层浸润性膀胱癌患者的安全性与初步有效性的多中心，非随机，非对照，开放I/II期研究

[Translation] A multicenter, non-randomized, non-controlled, open-label phase I/II study to observe the safety and preliminary efficacy of catumaxomab in patients with non-muscle invasive bladder cancer who have failed or are intolerant to BCG therapy

主要目的：观察评估卡妥索单抗膀胱灌注治疗BCG 治疗失败或不耐受的非肌层浸润性膀胱癌的安全性和初步疗效。次要目的：评估卡妥索单抗膀胱灌注的药代/药效动力学特征。

[Translation]

Primary objective: To observe and evaluate the safety and preliminary efficacy of intravesical instillation of catumaxomab in the treatment of non-muscle-invasive bladder cancer that has failed or is intolerant to BCG treatment. Secondary objective: To evaluate the pharmacokinetic/pharmacodynamic characteristics of intravesical instillation of catumaxomab.

Start Date11 Nov 2021

Sponsor / Collaborator

Guangzhou LintonPharm Co Ltd

[+2]

ChiCTR2100044274

/ RecruitingPhase 1/2IIT

A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who Have Failed or are Intolerant to Bacillus Calmette-Guerin (BCG) Vaccine

Start Date12 Jul 2021

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Catumaxomab

100 Translational Medicine associated with Catumaxomab

100 Patents (Medical) associated with Catumaxomab

125

Literatures (Medical) associated with Catumaxomab

31 Dec 2024·mAbs

A pivotal decade for bispecific antibodies?

Article

Author: Surowka, Marlena ; Klein, Christian

Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal. Nevertheless, only three bsAbs (catumaxomab, blinatumomab, emicizumab) were approved through the end of 2020. However, since then, 11 bsAbs received regulatory agency approvals, of which nine (amivantamab, tebentafusp, mosunetuzumab, cadonilimab, teclistamab, glofitamab, epcoritamab, talquetamab, elranatamab) were approved for the treatment of cancer and two (faricimab, ozoralizumab) in non-oncology indications. Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.

01 Jul 2024·Annals of Palliative Medicine

Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment

Review

Author: Ikegami, Takako ; Ishiki, Hiroto ; Ito, Tetsuya ; Yokomichi, Naosuke ; Kadono, Toru

BACKGROUND AND OBJECTIVEMalignant ascites (MA) is common in patients with advanced cancer, and about 60% of patients with MA experience distressing symptoms. In addition, MA has been identified as a poor prognostic factor, therefore, making the management of MA an important issue. We aimed to review literature describing MA provide a narrative synthesis of relevant studies.METHODSA literature search of articles published between 1971 and May 2023 was performed in PubMed, and Cochrane library using the words "ascites/malignant ascites" and the theme of each section. Authors independently selected the articles used and summarized. Finally, this manuscript was obtained consensus through discussed among all authors.KEY CONTENT AND FINDINGSThe pathophysiological mechanism of ascites formation involves increased vascular permeability and impaired fluid drainage through the lymphatic system, which explain the occurrence of peritoneal carcinomatosis, portal hypertension due to liver tumors, liver cirrhosis in the background of hepatocellular carcinoma, and Budd-Chiari syndrome caused by tumor occlusion of the hepatic vein. The efficacy and safety of various treatments and procedures have been investigated previously; however, no treatment guidelines have been established yet. Diuretics and paracentesis are often selected as the first lines of treatment. Intraperitoneal drug administration (catumaxomab, bevacizumab, aflibercept, hyperthermic intraperitoneal chemotherapy, triamcinolone), indwelling peritoneal catheters, peritoneovenous shunting, and cell-free and concentrated ascites reinfusion therapy are commonly used to manage refractory ascites. A new device for this purpose is alfapump, which transfers ascites fluid from the peritoneum into the urinary bladder. In addition, thoracic epidural analgesia may be effective for managing ascites-related symptoms.CONCLUSIONSDespite these options, no standard treatment for MA has been established yet because few trials have been conducted in this area. There are many issues to be investigated, and future research and treatment development are expected.

02 Dec 2023·Communications in Statistics - Simulation and Computation

Using biomarkers to allocate patients in a response-adaptive clinical trial

Article

Author: Bowen, S. ; Jackson, H. ; Jaki, T.

In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomization. The developed method uses a patient's biomarkers to alter the allocation probability to each treatment, in order to emphasize the benefit to the trial population. The method starts with an initial burn-in period of a small number of patients, who with equal probability, are allocated to each treatment. We then use a regression method to predict the best outcome of the next patient, using their biomarkers and the information from the previous patients. This estimated best treatment is assigned to the next patient with high probability. A completed clinical trial for the effect of catumaxomab on the survival of cancer patients is used as an example to demonstrate the use of the method and the differences to a controlled trial with equal allocation. Different regression procedures are investigated and compared to a randomized controlled trial, using efficacy and ethical measures.

News (Medical) associated with Catumaxomab

20 Feb 2025

·pipelinereview.com

Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites

MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline in immuno-oncology, and Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe. Under a licensing agreement, LINDIS has granted Pharmanovia the exclusive rights to bring catumaxomab to market and spearhead its launch across Europe. Catumaxomab, a first-in-class therapeutic, is specifically designed to treat malignant ascites in adults with certain types of cancer (epithelial cellular adhesion molecule (EpCAM)-positive carcinomas) who are not eligible for other systemic anticancer therapies. [i] Malignant ascites is a serious complication of advanced-stage cancers, characterised by the buildup of fluid in the abdomen, causing significant discomfort and severely impacting quality of life. The condition leads to considerable symptoms such as abdominal distension, pain, shortness of breath, fatigue, and fever. [ii] Stephen Deacon, Chief Scientific Officer at Pharmanovia commented; “This European Commission approval of catumaxomab is a significant milestone for people living with malignant ascites. Catumaxomab represents a novel therapeutic approach to this challenging condition. By targeting tumour cells and harnessing the power of the patient’s own immune system, we aim to improve quality of life for those living with malignant ascites in Europe.” Pharmanovia CEO, Dr. James Burt,highlighted the broader implications of the approval; “This approval not only brings a much-needed treatment to people with malignant ascites but also exemplifies Pharmanovia’s commitment to deepening our footprint within the specialty pharmaceutical sector. We are dedicated to delivering innovative and improved medicines to people in need, and this approval reinforces our position as a leader in providing access to essential therapies.” Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech, added : “We are delighted to receive marketing approval for catumaxomab. The approval highlights its potential to address the significant medical and treatment challenges faced by patients with malignant ascites. These individuals often endure invasive procedures like paracentesis, which carry risks of complications and severely impact their quality of life. Partnering with Pharmanovia to support commercialization, we are committed to ensuring that this groundbreaking therapy becomes accessible to all patients who can benefit from it.” -Ends- Notes to editors About Pharmanovia Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences. With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions. Lindis Biotech Lindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases. About CATUMAXOMAB Catumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons. On 17 th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®. Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body’s immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect. [iii] , [iv] The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial cancer) and is also known as a marker on tumor initiating cancer stem cells – a main driver of metastasis. Therefore, it is a promising approach for targeted treatment of various carcinomas. References [i] Korjuny | European Medicines Agency (EMA) (2024) European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny (Accessed: 11 December 2024). [ii] Ascites and Cancer – Side Effects (2024) Cancer.gov. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/ascites#signs-and-symptoms-of-ascites (Accessed: 11 December 2024). [iii] https://www.ema.europa.eu/en/documents/overview/removab-epar-summary-public_en.pdf [iv] Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1-10; 2013 SOURCE: Lindis Biotech

Drug ApprovalLicense out/inImmunotherapyAccelerated Approval

20 Nov 2024

·www.pharmaceutical-technology.com

Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab

The agreement enhances the oncology portfolio of Pharmanovia. Credit: Gorodenkoff/Shutterstock. Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional bi-specific monoclonal antibody treatment for malignant ascites, a rare complication of advanced-stage cancers. The agreement grants exclusive rights to Pharmanovia to market the antibody, designed for intraperitoneal administration in individuals with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas ineligible for additional systemic anticancer therapies. The company’s initiative to reintroduce catumaxomab to the market signifies its commitment to expanding its oncology portfolio. Alira Health served as the transaction advisor to Lindis Biotech exclusively, steering the strategic direction and final negotiations of the deal. Lindis Biotech CEO Dr Horst Lindhofer stated: “We are excited to partner with Pharmanovia to support the commercialisation of catumaxomab in Europe. Both companies share a firm belief in the profound impact this therapy can have on the lives of patients facing this devastating condition and uphold a steadfast commitment to making catumaxomab available to as many people as possible. “Pharmanovia’s supportive care focus, broad European platform and strong expertise in the oncology space make them the ideal partner for us. “We look forward to working together while continuing to further expand our pipeline in other indications with high unmet medical need, such as bladder cancer.” Catumaxomab originally received marketing authorisation under the Removab brand name in the European Union (EU) in April 2009. It was the first T-cell engager trifunctional antibody and the first drug to receive approval globally for malignant ascites treatment, demonstrating safety and anti-tumour efficacy in more than 2000 subjects. However, the therapy has not been on the market since 2014 and was withdrawn from the EU in June 2017 for commercial reasons. Pharmanovia CEO Dr James Burt stated: “We’re looking to change that through this partnership with Lindis Biotech, reintroducing catumaxomab to the market, subject to full regulatory approval. We’re excited to put our strong capabilities in new chemical entities (NCEs) to bring this important medicine to patients.”

License out/inDrug ApprovalImmunotherapyADCAccelerated Approval

19 Nov 2024

·pipelinereview.com

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

BASILDON, UK I November 19, 2024 I Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab, for the treatment of malignant ascites. The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy 1 . Malignant ascites is an abnormal accumulation of fluid in the peritoneal cavity that commonly arises from advanced-stage cancers. Dr Stephen Deacon, Chief Scientific Officer explains: “What is exciting about catumaxomab is that it has a novel targeted approach. This bispecific (anti-EpCAM x anti-CD3) trifunctional antibody combines the characteristics of classical monoclonal antibodies and bispecific molecules 2 . It binds directly to the tumour cells expressing EpCAM and then enhances the activation of the patient’s own immune system resulting in the killing of tumour cells.” Malignant ascites is a rare condition, most common in ovarian, pancreatic and gastric cancers, with an incidence of 20 to 50% of all cases. 3 Pharmanovia CEO, Dr. James Burt commented; “Our mission is to bring innovative and improved medicines to patients who need them, and this deal is the epitome of this. We have a first-in-class medicine, that can play a critical role in cancer supportive care that has previously been approved but is no longer available. We’re looking to change that through this partnership with Lindis Biotech, reintroducing catumaxomab to the market, subject to full regulatory approval. We’re excited to put our strong capabilities in New Chemical Entities (NCEs) to bring this important medicine to patients.” “We are excited to partner with Pharmanovia to support the commercialisation of catumaxomab in Europe. Both companies share a firm belief in the profound impact this therapy can have on the lives of patients facing this devastating condition and uphold a steadfast commitment to making catumaxomab available to as many people as possible,” said Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech . “Pharmanovia’s supportive care focus, broad European platform and strong expertise in the oncology space make them the ideal partner for us. We look forward to working together while continuing to further expand our pipeline in other indications with high unmet medical need, such as bladder cancer.” Prof. Carsten Bokemeyer, Director of the Department of Medical Oncology and Hematology at the University of Hamburg, UKE stated: “The clinical management of malignant ascites remains a distressing problem in the medical field. Unfortunately, to this day, no generally accepted, evidence-based treatment guidelines or specific management recommendations for MA exist and there has been little progress to ease the burden for patients and improve their quality of life. Thus, the availability of catumaxomab as a specific tumour-directed therapy is a clear benefit for patients in this difficult situation. Catumaxomab reduces the need for punctures, improves quality of life, and even seems to improve life expectancy in a number of cases.” Catumaxomab received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting with EU marketing authorization expected end of 2024. If approved, it would become the only drug approved for the specific and cancer-directed treatment of malignant ascites. About Pharmanovia Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences. With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions. About Lindis Biotech Lindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases. About CATUMAXOMAB Catumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. catumaxomab was the first T cell engager trifunctional antibody and the first drug in the world approved specifically for the treatment of MA and has since proven its safety and anti-tumor efficacy in more than 2000 patients. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons. On 17 th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®. Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches to and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body’s immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect 4,5 . References 1 https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny 2 https://pmc.ncbi.nlm.nih.gov/articles/PMC2840231/ 3 Ref: BMJ, https://spcare.bmj.com/content/13/e3/e1292 4 https://www.ema.europa.eu/en/documents/overview/removab-epar-summary-public_en.pdf 5 Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1–10; 2013; https://pubmed.ncbi.nlm.nih.gov/23955093/ SOURCE: Lindis Biotech

License out/inDrug ApprovalImmunotherapy

100 Deals associated with Catumaxomab

External Link

KEGG	Wiki	ATC	Drug Bank
D09207	Catumaxomab	L01XC09	DB06607

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EpCAM positive Solid Tumors	European Union	Lindis Biotech Gmbh	10 Feb 2025
EpCAM positive Solid Tumors	Norway	Lindis Biotech Gmbh	10 Feb 2025
EpCAM positive Solid Tumors	Iceland	Lindis Biotech Gmbh	10 Feb 2025
EpCAM positive Solid Tumors	Liechtenstein	Lindis Biotech Gmbh	10 Feb 2025
Malignant ascites	European Union	Lindis Biotech Gmbh	10 Feb 2025
Malignant ascites	Iceland	Lindis Biotech Gmbh	10 Feb 2025
Malignant ascites	Liechtenstein	Lindis Biotech Gmbh	10 Feb 2025
Malignant ascites	Norway	Lindis Biotech Gmbh	10 Feb 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malignant ascites	Phase 1	Norway	Neovii Biotech GmbH	20 Apr 2009
Malignant ascites	Phase 1	European Union	Neovii Biotech GmbH	20 Apr 2009
Malignant ascites	Phase 1	Iceland	Neovii Biotech GmbH	20 Apr 2009
Malignant ascites	Phase 1	Liechtenstein	Neovii Biotech GmbH	20 Apr 2009
Ovarian Cancer	Phase 1	-	Neovii Biotech GmbH	01 Sep 2004
Stomach Cancer	Phase 1	-	Neovii Biotech GmbH	01 Sep 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04819399 (CATUNIBLA, ESMO2024) Manual	Phase 1	Non-Muscle Invasive Bladder Neoplasms	27	Catumaxomab 50 μg	(xejzudxszu) = Pts did not experience any drug-related SAE, but procedure-related urinary tract infection was common. All CAT induced AE were mild or moderate (gr 1-2). Serum cytokines were typically not detectable. jrzonmaucb (zseswqkatr )	Positive	15 Sep 2024
NCT04819399 (CATUNIBLA, Corporate Publications) Manual	Phase 1	Non-Muscle Invasive Bladder Neoplasms	7	Catumaxomab (level 2 and 3 dose groups of 70 μg and 100 μg)	(edgsctvluj) = only of grade 1-2 eybzkwpgha (djvvlmjsrn )	Positive	14 Nov 2022
NCT04819399 (CATUNIBLA, ASCO2022) Manual	Phase 1	Non-Muscle Invasive Bladder Neoplasms	7	Catumaxomab	(fskawzvtbp) = pynjebyqpo jnjevncqjb (uzszgijvkl ) View more	Positive	02 Jun 2022
NCT04222114 (ASCO2022)	Phase 1	Advanced gastric carcinoma	17	Catumaxomab 10 μg	(aobugovgty) = teoqhwfmgz yleaefvxks (vppirvmhil, 38 - 166) View more	Positive	02 Jun 2022
NCT01504256 (CatuNeo, Pubmed \| Med J Aust) Manual	Phase 2	Peritoneal Neoplasms \| Stomach Cancer	31	5-fluorouracil+leucovorin+oxaliplatin+docetaxel+FLOT+catumaxomab	(qqrjvfrlqe) = pyhnzgsrow znvzpxlaza (gpkcuotwlk ) View more	Positive	01 Aug 2018
NCT01504256 (CatuNeo, Pubmed \| Med J Aust) Manual	Phase 2	Peritoneal Neoplasms \| Stomach Cancer	31	FLOT+catumaxomab	(qqrjvfrlqe) = hkcoywtvrk znvzpxlaza (gpkcuotwlk ) View more	Positive	01 Aug 2018
NCT00326885 (Pubmed \| Int J Gynecol Cancer)	Phase 2	Malignant ascites	32	Catumaxomab	vmxcrjmqvy(rfksqgcsit) = lgguflgnub xyxcencpni (yjdmzuxvzf ) View more	-	01 Nov 2014
NCT01246440 (GEICO 1001, ASCO2014)	Phase 2	Recurrent ovarian cancer Consolidation	46	Intraperitoneal Catumaxomab	(izktrmslds) = uospwbikpf jmcekljtqw (qzvsevyvdk ) View more	-	20 May 2014
SITC2014	Not Applicable	Tissue infiltration EpCAM positive \| CD45 positive	27	Catumaxomab	hdfuhaifjb(gaskfrxtwo) = zjgiizqawp igpyvpnseq (kvgpdwwgra )	Positive	12 Mar 2014
ASCO2013	Phase 3	Recurrent ovarian cancer \| Malignant ascites	109	Catumaxomab followed by systemic chemotherapy (CTX)	(qvhkrlgieh) = lrzvjmnvto oprxggotrp (cxscxbzqal ) View more	-	20 May 2013
ASCO2013	Phase 3	Malignant ascites	389	Catumaxomab	(qwoumtuajs) = evyntyunxo drdhoorixr (gijbamizmf ) View more	-	20 May 2013
ASCO2013	Phase 3	Malignant ascites	389	catumaxomab (Control)	(qwoumtuajs) = bvosdhkglg drdhoorixr (gijbamizmf ) View more	-	20 May 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis